MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies ...
Just one year after identifying early leads for its oral FSH program, Celmatix has nominated its first lead after the compound demonstrated oral bioavailability and biological activity in the gold ...
Leishmaniasis, a neglected tropical disease prevalent across 90 countries, affects approximately 12 million people worldwide, ...
CUMBERLAND, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases characterized ...
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker. Two additional scientific abstracts from the NATIVE Phase IIb clinical ...
Hosted on MSN
Q&A: Designing a backup for a drug compound to improve memory loss in people with Alzheimer's disease
Cognitive dysfunctions are common symptoms for Alzheimer's disease, schizophrenia, and other disorders of the central nervous system. Most people are familiar with the memory problems as one type of ...
Individual food compounds, rather than broad food groups, may have important effects on IBD disease activity. A machine learning model identified food compounds associated with modulating disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback